666831-19-2

Upstream product

• 635319-09-4 tert-butyl (3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 666831-17-0 (3R,4S)-1-[(7-benzyloxymethyl-6-tert-butoxy-9-deazapurin-9-yl)methyl]-3-hydroxy-4-methylthiomethylpyrrolidine hydrochloride 
• 666831-18-1 (3R,4S)-1-acetoxy-[(7-benzyloxymethyl-6-tert-butoxy-9-deazahypoxanthin-9-yl)methyl]-4-methylthiomethylpyrrolidine 
• 666831-24-9 tert-butyl (3R,4R)-3-hydroxy-4-[(methanesulfonyloxy)methyl]pyrrolidine-1-carboxylate 
• 666831-26-1 (3R,4S)-tert-butyl 3-hydroxy-4-((methylthio)methyl)pyrrolidine-1-carboxylate 

Downstream Products

• 653592-04-2 (3R,4S)-1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-((methylthio)methyl)pyrrolidin-3-ol 

Relevant academic research and scientific papers

Second generation transition state analogue inhibitors of human 5′-methylthioadenosine phosphorylase

The polyamine biosynthetic pathway is a therapeutic target for proliferative diseases because cellular proliferation requires elevated levels of polyamines. A byproduct of the synthesis of spermidine and spermine is 5′-methylthioadenosine (MTA). In humans

INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND NUCLEOSIDASES

The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5'-methylthioadenosine phosphorylases (MTAP), 5'-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds